In addition to reducing respiratory syncytial virus (RSV)–related hospitalizations and emergency department (ED) visits, nirsevimab (Beyfortus) may also reduce these events when they’re linked to other lower respiratory tract infections…
Nirsevimab may help prevent severe respiratory illnesses beyond RSV in infants, young kids
